Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

DISEASE CHARACTERISTICS: Histologically confirmed diagnosis of any of the following hematologic malignancies: Acute myeloid leukemia (AML) meeting any of the following criteria: First complete remission with high-risk karyotype Translocations t(15;17) allowed only if failed first-line induction therapy OR molecular evidence of persistent disease exists Translocations t(8;21) and inv(16) allowed only if failed first-line induction therapy Second or subsequent complete remission Minimal residual disease* Acute lymphoblastic leukemia meeting any of the following criteria: Failed induction therapy and has minimal residual disease* by salvage therapy First complete remission with high-risk karyotype (e.g., t[4;11] or t[9;22]) Relapsed disease allowed provided a second or subsequent complete remission or minimal residual disease* is achieved Chronic myelogenous leukemia meeting any of the following criteria: Persistent or relapsed disease after 1 year of imatinib mesylate therapy Accelerated phase or blast crisis Blast crisis allowed after reinduction chemotherapy places disease in chronic phase Myelodysplastic syndromes meeting any of the following criteria: Refractory to medical management Cytogenetic abnormalities predictive of transformation into acute leukemia, including 5q-, 7q-, monosomy 7 and trisomy 8, or evidence of evolution to AML (e.g., refractory anemia with excess blasts (RAEB) or RAEB in transformation) Non-Hodgkin's lymphoma or Hodgkin's lymphoma meeting any of the following criteria: Beyond first complete remission or failed primary induction therapy and demonstrated sensitivity to therapy during the 6 months before transplantation Recurrent disease after autologous stem cell transplantation Must be at least 3 months posttransplantation Cyclin D1+ mantle cell lymphoma allowed after induction therapy and in first remission Multiple myeloma meeting either of the following criteria: Refractory or relapsed disease Residual disease after autologous transplantation Chronic lymphocytic leukemia (CLL) meeting all of the following criteria: Peripheral blood absolute lymphocyte count greater than 5,000/mm^3 Small to moderate size lymphocytes and less than 55% pro-lymphocytes, atypical lymphocytes, or lymphoblasts morphologically B-cell or T-cell Myeloproliferative disorders, including myelofibrosis Philadelphia negative Availability of a HLA-A, B, and DR identical family donor OR HLA-A, B, and DR genetically matched unrelated donor Must meet 1 of the following criteria: At least 55 years of age at time of transplantation Received extensive prior therapy (i.e., more than 1 year of alkylator therapy or more than 2 different prior salvage regimens) or stem cell transplantation with myeloablative conditioning (either autologous or allogeneic) Presenting with comorbid condition (e.g., abnormal cardiac, pulmonary, or renal function and/or prior life-threatening infection) that precludes eligibility for enrollment in allogeneic transplantation protocols with full ablation conditioning No active CNS disease NOTE: *Defined as having no circulating blasts, absolute neutrophil count greater than 1,000/mm3 and less than 10% blasts in bone marrow at least 3 weeks after last systemic chemotherapy PATIENT CHARACTERISTICS: Age See Disease Characteristics Over 18 Performance status ECOG 0-2 Life expectancy At least 3 months Hematopoietic See Disease Characteristics Hepatic Bilirubin no greater than 2.0 mg/dL ALT/AST no greater than 4 times normal Renal See Disease Characteristics Creatinine less than 2.0 mg/dL OR Creatinine clearance at least 50 mL/min Cardiovascular See Disease Characteristics Normal cardiac function by echocardiogram or radionuclide scan Shortening fraction or ejection fraction at least 40% of normal Pulmonary See Disease Characteristics DLCO at least 60% FEV_1 greater than 50% of predicted Pulse oximetry greater than 85% Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception HIV negative No uncontrolled active infection PRIOR CONCURRENT THERAPY: Biologic therapy See Disease Characteristics At least 2 weeks since prior biologic response modifiers, signal transduction inhibitors, or monoclonal antibodies Chemotherapy See Disease Characteristics At least 4 weeks since prior systemic conventional chemotherapy Endocrine therapy Not specified Radiotherapy Not specified Surgery Not specified Other Recovered from prior therapy No concurrent sun block/sunscreen or any cosmetic that may act as a sunscreen (e.g., lotion with SPF) on the days of scheduled ultraviolet-B light therapy